To determinate feasibility, safety and outcome with convalescent plasma in patients with severe COVID-19 penumonia
COVID-19 convalescent plasma will be infused to patients with severe COVID-19 pneumonia to
determine feasibility, safety and clinical outcome efficacy by survival at-28 days. Data will
be compared with match control arm patients without plasma infusion
Biological: COVID19 convalescent plasma infusion
intravenous infusion of 300-600 mL of convalescent plasma with an antibody title more than 3 according to chemiluminescent microparticle immunoassay (Architect Plus Abbott)
Inclusion Criteria:
- Adult patients ≥18, and non-pregnant women
- Severe or critical COVID-19 disease define by one or more of the following: blood
oxygen saturation ≤ 94% on supplemental oxygen by nasal cannula at least 3 L/min,
non-rebreathing mask (NRO2-mask) or on noninvasive ventilation; and pulmonary
infiltrates with >50% increase within 24 to 48 hours in chest-X-ray or chest CT.
Life-threatening disease was defined as one or more of the following: respiratory
failure on mechanical ventilation with PaO2 / FiO2 less than 300 mm Hg, septic shock,
and/or multiple organ dysfunction.
- 10 days from the onset of symptoms or ≤ 7 days on mechanical ventilation. -
Exclusion Criteria:
- More than 10 days from symptoms onset or more than 7 days on mechanical ventilation
- Pregnancy
- Contraindication for plasma infusion because anaphylaxis history
- Patients with high risk of circulatory overload
- Limitation of therapeutic efforts
- Refractory shock define by norepinephrine dose more than 1 ug/k/min
- SOFA score more than 15 points at the moment of the protocol inclusion i Coagulopathy
with requirements of plasma infusion
Centro de Educación Médica e Investigaciones Clínicas
Buenos Aires, Argentina